A selective, reversible IBAT inhibitor at a key site of enterohepatic circulation1,2
Role of IBAT3
- The IBAT regulates BA pool size, with 95% of BA reabsorbed by the IBAT
By targeting the IBAT, Bylvay2,3*
- Blocks reabsorption of BAs and reroutes them via fecal excretion
- Helps reduce the BA pool recirculating to the liver
*Although the complete mechanism of Bylvay is unknown, it may involve inhibition of the IBAT, which results in decreased reuptake of bile salts, as observed by a decrease in sBA.1
Bylvay is selective, with minimal systemic exposure1,3
- Bylvay acts locally in the small intestine
- Bylvay is minimally absorbed in plasma following oral administration, and no accumulation of Bylvay was observed following once-daily dosing
- Highly efficient IBAT inhibition at a starting dose of 40 mcg/kg/day in PFIC or 120 mcg/kg/day in PFIC or 120 mcg/kg/day in ALGS
See how Bylvay works to reduce all levels of cholestatic pruritus
ALGS=Alagille syndrome; BA=bile acid; IBAT=ileal bile acid transporter; PFIC=progressive familial intrahepatic cholestasis; sBA=serum bile acid.
References:
- Bylvay Prescribing Information. Boston, MA: Albireo Pharma, Inc.; 2023.
- Kamath BM, Stein P, Houwen RHJ, Verkade HJ. Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis. Liver Int. 2020;40(8):1812-1822.
- Data on file A4250-005. Boston, MA: Albireo Pharma, Inc.
- Bylvay Prescribing Information. Boston, MA: Albireo Pharma, Inc.; 2023.
- Kamath BM, Stein P, Houwen RHJ, Verkade HJ.
Potential of ileal bile acid transporter inhibition as a
therapeutic target in Alagille syndrome and
progressive familial intrahepatic cholestasis. Liver Int.
2020;40(8):1812-1822. - Data on file A4250-005. Boston, MA: Albireo Pharma,
Inc.